Breaking: FTC Seeks More Info on Pfizer's Seagen Merger Plan
- July 15th, 2023
- 516 views
Seagen Inc. (Nasdaq: SGEN) and Pfizer Inc. (NYSE: PFE) have encountered a regulatory hurdle in their planned merger. According to a regulatory filing with the SEC, both companies received a Second Request from the Federal Trade Commission (FTC) on July 14, 2023, regarding additional information and documentary materials related to the merger. This request triggers an extension of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The companies aim to comply promptly and cooperate with the FTC to advance the review process.
Furthermore, the merger has also been referred to the European Commission (EC) for review under Article 4(5) of the EU Merger Regulation. The EC has accepted jurisdiction, making approval from the EC a crucial condition for the completion of the merger.
Despite the regulatory challenges, Seagen and Pfizer expect the merger to be finalized in late 2023 or early 2024, subject to meeting customary closing conditions and obtaining required regulatory approvals.
On Friday, $SGEN closed at $198.00 (+0.43%), and $PFE closed at $36.32 (+0.72%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Tags
Post Your Comments
Want To Find Some News?
Recent Posts
-
February 27th, 2026February 26th, 2026
Treasury Sanctions Nicaraguan Officials Enabling the Murillo-Ortega Dictatorship's Repression
February 26th, 2026Kansas City Storm Names Cecil Stockdale as Head Coach for 2026 NJCP Season
February 26th, 2026Dallas Stampede Announces Open Tryouts for Scholarship Opportunities
February 25th, 2026
Member Login